Kim Jong-Hoon, Kim Jung-Hyun, Park Pil-Whan, Machann Jürgen, Roden Michael, Lee Sheen-Woo, Hwang Jong-Hee
Department of Psychiatry, Gil Medical Center, Gachon University School of Medicine, Gachon University, Incheon, Republic of Korea.
Neuroscience Research Institute, Gachon University, Incheon, Republic of Korea.
Psychopharmacology (Berl). 2017 Jun;234(12):1923-1932. doi: 10.1007/s00213-017-4598-5. Epub 2017 Mar 18.
Although antipsychotic treatment often causes weight gain and lipid abnormalities, quantitative analyses of tissue-specific body fat content and its distribution along with adipokines have not been reported for antipsychotic-treated patients.
The purposes of the present study were to quantitatively assess abdominal and liver fat in patients with schizophrenia on antipsychotic treatment and age- and body mass index (BMI)-matched healthy controls and to evaluate their associations with plasma leptin and adiponectin levels.
In 13 schizophrenia patients on antipsychotic treatment and 11 age- and BMI-matched controls, we simultaneously quantified visceral and subcutaneous fat content using T1-weighted magnetic resonance imaging and liver fat content by H magnetic resonance spectroscopy. Associations of tissue-specific fat content with plasma levels of leptin and adiponectin were evaluated.
Plasma adiponectin level (μg/mL) was not statistically different between groups (7.02 ± 2.67 vs. 7.59 ± 2.92), whereas plasma leptin level (ng/mL) trended to be higher in patients than in controls (11.82 ± 7.89 vs. 7.93 ± 5.25). The values of liver fat (%), visceral fat (L), and subcutaneous fat (L) were 9.64 ± 8.03 vs. 7.07 ± 7.35, 4.41 ± 1.64 vs. 3.31 ± 1.97, and 8.37 ± 3.34 vs. 7.16 ± 2.99 in patients vs. controls, respectively. Liver fat content was inversely correlated with adiponectin in controls (r = - 0.87, p < 0.001) but not in patients (r = - 0.26, p = 0.39). In both groups, visceral fat was inversely associated with adiponectin (controls : r = - 0.66, p = 0.03; patients : r = - 0.65, p = 0.02), while subcutaneous fat was positively correlated with leptin (controls : r = 0.90, p < 0.001; patients : r = 0.67, p = 0.01).
These findings suggest that antipsychotic treatment may disrupt the physiological relationship between liver fat content and adiponectin but does not essentially affect the associations of adiponectin and leptin with visceral and subcutaneous compartments.
尽管抗精神病药物治疗常导致体重增加和脂质异常，但尚未有关于抗精神病药物治疗患者组织特异性体脂含量及其分布以及脂肪因子的定量分析报道。
本研究的目的是定量评估接受抗精神病药物治疗的精神分裂症患者以及年龄和体重指数（BMI）匹配的健康对照者的腹部和肝脏脂肪，并评估它们与血浆瘦素和脂联素水平的关联。
在13名接受抗精神病药物治疗的精神分裂症患者和11名年龄及BMI匹配的对照者中，我们使用T1加权磁共振成像同时定量内脏和皮下脂肪含量，并通过氢磁共振波谱法定量肝脏脂肪含量。评估组织特异性脂肪含量与血浆瘦素和脂联素水平的关联。
两组间血浆脂联素水平（μg/mL）无统计学差异（7.02±2.67对7.59±2.92），而患者的血浆瘦素水平（ng/mL）有高于对照者的趋势（11.82±7.89对7.93±5.25）。患者与对照者的肝脏脂肪（%）、内脏脂肪（L）和皮下脂肪（L）值分别为9.64±8.03对7.07±7.35、4.41±1.64对3.31±1.97、8.37±3.34对7.16±2.99。在对照者中，肝脏脂肪含量与脂联素呈负相关（r = -0.87，p < 0.001），但在患者中无此相关性（r = -0.26，p = 0.39）。在两组中，内脏脂肪均与脂联素呈负相关（对照者：r = -0.66，p = 0.03；患者：r = -0.65，p = 0.02），而皮下脂肪与瘦素呈正相关（对照者：r = 0.90，p < 0.001；患者：r = 0.67，p = 0.01）。
这些发现表明，抗精神病药物治疗可能会破坏肝脏脂肪含量与脂联素之间的生理关系，但基本上不影响脂联素和瘦素与内脏和皮下脂肪组织的关联。
